Kinevant Sciences, a wholly-owned subsidiary of Roivant, is focused on developing new therapies for rare auto-immune diseases, initially targeting sarcoidosis with an anti-GM-CSF monoclonal antibody (namilumab). The Company will initiate a clinical trial in pulmonary sarcoidosis in H1 2022. Sarcoidosis is a multi-organ autoimmune disease with poor treatment options that affects up to 200,000 people in the U.S. The long-term vision for Kinevant is to successfully develop and commercialize namilumab for sarcoidosis as well as develop a portfolio of candidates for other auto-immune or inflammatory orphan diseases.
Roivant’s mission is to systematically reduce the time, cost, and risk of delivering new medicines to market by accelerating the development of promising drug candidates to improve the lives of patients and their families. Since its inception in 2014 Roivant has achieved the following critical milestones: launched over 20 portfolio companies (Vants); 5 successful IPOs; $3B partnership with global pharma; pipeline of over 40 assets across various modalities and therapeutic areas; 8 successful phase 3 readouts since 2019. Traditionally, Roivant provides all the capital required for Vant operations until the Vant becomes a public company. Roivant attracts, retains, and motivates entrepreneurial company builders that have deep domain expertise with competitive compensation and benefits, including stock option grants in the Vant.
The Head of Immunology Research will establish and lead the nonclinical and translational research department for the company. In the short term this will encompass the in vitro and in vivo research strategy to further the mechanistic understanding of the role of namilumab in sarcoidosis, create the research substrate on which to base future clinical development decisions for novel indications, and identify additional promising candidates. The Head of Immunology Research will also play a key role in identifying and evaluating new candidates in auto-immune diseases to continue to expand our pipeline.
What You'll Do:
- Be the Company’s in-house expert on the role of dysregulated GM-CSF biology in auto-immune and -inflammatory diseases
- Lead development programs from the nonclinical and translational perspective by articulating a deep understanding of the underlying immunobiology and lead the development of a research agenda for Kinevant
- Lead the development, conduct, analyses, and reporting of appropriate research studies that further the understanding of the role of namilumab in sarcoidosis
- Lead the development, conduct, analyses, and reporting of appropriate research studies that further the understanding of the role of GM-CSF in potential future indications
- Partner with Nonclinical, Toxicology, Clinical and other stakeholders on the design and conduct of the namilumab development plan including translational, bio-analytical, and clinical plans
- Work closely with other functions to support programs in active development toward value inflection points (i.e. FIH, POC, BLA, registration) at Kinevant
- Author/review relevant subsections of regulatory documents and interact with regulatory authorities
- Provide oversight to external consultants as needed
- Be responsible for presentations at scientific conferences and publication of the Company’s research
Who You Are:
- PhD in relevant biological sciences (Immunology related field)
- 10+ years experience in discovery and development
- Excellent understanding of relevant disease models and demonstrated expertise in immunological mechanisms of action is a plus
- Integrated understanding of drug development and the role of having an integrated scientific research plan within the broader pharmaceutical development landscape for namilumab. Prior experience on programs that led to successful IND opening trials, pivotal trials, registration, or post-marketing studies preferred
- Excellent written and oral communication skills
- Proven ability to independently manage multiple projects/tasks
- Ability to travel to CRO partners (as dictated by specific study needs) on an as-needed basis